Aromatase Inhibition and Breast Cancer

by William L. Miller (Editor), Richard Santen (Editor)

Presents evidence that letrozole, anastrozole, and exemestane have proven efficacy as second-line therapy and indicate increased antitumor effects and less toxicity than older aromatase inhibitors and progestins!
This reference provides a state-of-the-art assessment of drugs that inhibit the synthesis of estrogens-particularly agents used to treat breast cancer-and demonstrates how the endocrinological effects of the new generation of inhibitors translate into clinical benefits.
Highlights recent key research aimed at developing novel reagents and technology to optimize drug therapies and expand their clinical applications.
With contributions from over 75 international experts, Aromatase Inhibition and Breast Cancer

322 pages, Hardcover

First published September 1, 2000